Delcath Systems Inc. (DCTH) has delivered a strong performance in the first quarter of 2025, marked by significant revenue growth, its first-ever quarterly net income, and positive cash flow.
The company develops and commercializes interventional oncology treatments for liver cancers. Its flagship product is HEPZATO KIT, which is comprised of the chemotherapeutic drug Melphalan and Delcath's proprietary Hepatic Delivery System (HDS).
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.